TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: mean treatment effect for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altered segmental relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global diastolic dysfunction (DD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blockade of AT(1) receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estimated insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RSSA percent decrement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1RM ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OPA titers for common serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of life data
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Receipt of screening tests
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EPS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: patients' self evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: width of the subarachnoid space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: head circumference at 36 weeks' CGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body weight at 36 weeks' CGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental health domains of HRQL
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: somatic symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Peak plantar pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: logCRP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant difference in tic severity between THC and placebo groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days without ventilator use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal function alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: frequency of abnormal bleedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in periorbital oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage increase in green-labeled purchases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean C(max) of ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean AUC(0-infinity) of ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-rated drug effect of S-ketamine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in child behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHtR as an indicator of future adverse risk
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of smoking initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical impact of thienopyridine interruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intolerable pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hysteroscopy failure due to stenosis
Endpoint domain: Adverse events/effects
Primary endpoint: Lymphocyte subpopulations (CD19, CD71, CD97, CD134, CD137)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Residual anteroposterior laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pivot shift test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognition (ADAS-cog/11)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional ability (DAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior (NPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the assay for pulmonary specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the assay for extrapulmonary specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endotoxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor necrosis factor (TNF)‐α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LVMi regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: predicted survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean value of Mg intake related to Ca balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean value of Mg intake related to P balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerance of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of flushing, headache, neck pain, and atrioventricular block
Endpoint domain: Adverse events/effects
Primary endpoint: Cure rate of bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of adverse respiratory events
Endpoint domain: Adverse events/effects
Primary endpoint: movement during the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Withdrawal due to worsening asthma
Endpoint domain: Adverse events/effects
Primary endpoint: Strength of the untrained left Biceps Brachii
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cross-activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Surface hardness (SH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knoop hardness number (ΔKHN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forward head posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in prescribing errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEP amplitude in the left tibialis anterior muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective Ce of remifentanil for successful LMA insertion (EC50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective Ce of remifentanil for successful LMA insertion (EC95)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postprocedural myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement in neck-shoulder-limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of producing the effect
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CDR score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Urination symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearing of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed of naming high frequency words
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stay-in-ICU duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospitalisation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-bleeding rates
Endpoint domain: Adverse events/effects
Primary endpoint: Stride length improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-diastolic volume (EDV) at peak HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serotype-specific antibody concentration >0.15 microg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in nocturnal cough frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean daily urgency incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HUI‐3 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Grade of fiberoptic view
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of recipients with serum bactericidal assay titers of 1:8 or higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of recipients with anti‐polyribosylribitol phosphate antibody levels of ≥ 1.0 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of pain, redness, and swelling at injection sites
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in emotional stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean CSp radiation doses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean LOSs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Difference in medication usage
Endpoint domain: Adverse events/effects
Primary endpoint: mean peak FDO2 during ventilation‐only/full CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergence delirium (measured as PAED score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discharge from recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement of hemorrheologic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tracking performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: divided attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Increase in [THb]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Events (SAEs) per patient
Endpoint domain: Adverse events/effects
Primary endpoint: number of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: perceptions of diabetes severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived diabetes risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Arousal and desire improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Orgasm, enjoyment, and satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: perceived likelihood of experiencing health effects from smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: intentions to quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cmax and AUCτ values of gemigliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and AUCτ values of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and AUCτ values of irbesartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive intracranial haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of unfavourable outcome on the Glasgow Outcome Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: biochemical and clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stone-free rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: patency rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: tumor-free rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean SSI decrease over baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical dilatation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score 30 minutes after the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resumption of normal menstrual flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: spine and femoral neck BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of high-grade prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Risk of low-grade prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Change in PANSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in MET.min/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of meeting PA recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beta-cell function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma GSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in symptoms of sciatica
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detrusor pressure at maximal urinary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urological outcomes
Primary endpoint: TRUS volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urological outcomes
Primary endpoint: stand-walk-sit score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: carer strain
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Organism eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain score during the first 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption during 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mental Component Summary (MCS) values
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical Component Summary (PCS) values
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants achieving 25(OH)D levels greater than 30 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion with a 30% or greater decrease in iPTH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 6- and 12-month survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Neutrophil respiratory burst activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean nausea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequacy of chest compression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: stone clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: interval to the elimination of stone fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Virologic failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician severity ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Donation attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Donation intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: post-operative atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in clinical signs of hypertrophic scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PODSI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional concordance values in myocardial walls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence rate of respiratory tract infections (RTIs)
Endpoint domain: Adverse events/effects
Primary endpoint: possession of or revision of an asthma action plan
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: albumin/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correct odor identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast milk volume load (BMVL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of women achieving normotensive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skill in performing pelvic examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean score of total Y-BOCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum testosterone suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ankle circumference measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of understanding and usefulness of the smartphone site
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reply rate for reporting the frequency of massage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant mean wrinkle correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reduction in low-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median Local Progression-Free Survival (L-PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Total hospitalization cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alcohol abstinence self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in cigarette smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative endometritis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean postoperative hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Torque capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Sleep Time (TST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: VAS values at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic VAS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue dose consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mortality at 3 days
Endpoint domain: Mortality/survival
Primary endpoint: Composite of death or heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Days of paid employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 1-minute Apgar score <7
Endpoint domain: Adverse events/effects
Primary endpoint: hypotonic after delivery
Endpoint domain: Adverse events/effects
Primary endpoint: need for bag and mask resuscitation
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent major adverse cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to perceived headache relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full headache relief within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes